Circulating MiR-125b as a Marker Predicting Chemoresistance in Breast Cancer
Open Access
- 16 April 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (4), e34210
- https://doi.org/10.1371/journal.pone.0034210
Abstract
Chemotherapy is an important component in the treatment paradigm for breast cancers. However, the resistance of cancer cells to chemotherapeutic agents frequently results in the subsequent recurrence and metastasis. Identification of molecular markers to predict treatment outcome is therefore warranted. The aim of the present study was to evaluate whether expression of circulating microRNAs (miRNAs) can predict clinical outcome in breast cancer patients treated with adjuvant chemotherapy. Circulating miRNAs in blood serum prior to treatment were determined by quantitative Real-Time PCR in 56 breast cancer patients with invasive ductal carcinoma and pre-operative neoadjuvant chemotherapy. Proliferating cell nuclear antigen (PCNA) immunostaining and TUNEL were performed in surgical samples to determine the effects of chemotherapy on cancer cell proliferation and apoptosis, respectively. Among the miRNAs tested, only miR-125b was significantly associated with therapeutic response, exhibiting higher expression level in non-responsive patients (n = 26, 46%; p = 0.008). In addition, breast cancers with high miR-125b expression had higher percentage of proliferating cells and lower percentage of apoptotic cells in the corresponding surgical specimens obtained after neoadjuvant chemotherapy. Increased resistance to anticancer drug was observed in vitro in breast cancer cells with ectopic miR-125b expression; conversely, reducing miR-125b level sensitized breast cancer cells to chemotherapy. Moreover, we demonstrated that the E2F3 was a direct target of miR-125b in breast cancer cells. These data suggest that circulating miR-125b expression is associated with chemotherapeutic resistance of breast cancer. This finding has important implications in the development of targeted therapeutics for overcoming chemotherapeutic resistance in novel anti-cancer strategies.Keywords
This publication has 56 references indexed in Scilit:
- MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) ExpressionOnline Journal of Public Health Informatics, 2010
- MicroRNA-155 Regulates Cell Survival, Growth, and Chemosensitivity by Targeting FOXO3a in Breast CancerOnline Journal of Public Health Informatics, 2010
- Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem CellsCell, 2009
- miR‐29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasisEMBO Reports, 2009
- E2F – at the crossroads of life and deathTrends in Cell Biology, 2008
- MicroRNA-221/222 Negatively Regulates Estrogen Receptorα and Is Associated with Tamoxifen Resistance in Breast CancerOnline Journal of Public Health Informatics, 2008
- Life and death decisions by the E2F transcription factorsCurrent Opinion in Cell Biology, 2007
- An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2007
- Oncomirs — microRNAs with a role in cancerNature Reviews Cancer, 2006
- Combinatorial microRNA target predictionsNature Genetics, 2005